MedTrace Logo

PET/MRI in the Diagnosis of Chronic Pain

NCT03556137 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2023-07-20

No results posted yet for this study

Summary

Several studies have implicated involvement of sigma-1 receptors (SR1s) in the generation of chronic pain, while others are investigating anti SR1 drugs for treatment of chronic pain. Using \[18F\]-FTC-146 and positron emission tomography/magnetic resonance imaging (PET/MRI), the investigators hope to identify the source of pain generation in patients with chronic pain. The purpose of this study is to compare the uptake of \[18F\]FTC-146 in healthy volunteers to that of individuals suffering from chronic pain.

Conditions

  • Neuropathic Pain
  • Nociceptive Pain
  • Mixed Pain (Nociceptive and Neuropathic)
  • Spinal Pain
  • Radiculopathy
  • Myelopathy
  • Neurogenic Claudication

Interventions

DRUG

[18F]FTC-146

Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.

Sponsors & Collaborators

Principal Investigators

  • Anand Veeravagu, MD · Stanford University Department of Neurosurgery

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03556137 on ClinicalTrials.gov